Background: Despite the availability of vast group of drugs, treatment of depression still remains unsatisfactory, largely due to differential efficacy of antidepressants at adequate doses resulting in treatment refractive depression. In addition, serious adverse effects of anti-depressants also lead to early withdrawal from treatment. One more important concern is the therapeutic lag of nearly 3-4 weeks, before some appreciable clinical effect. Therefore, newer agents with good safety profile, rapid onset of action and with substantial benefits in treating patients who are either refractory or resistant to conventional therapy, need to be explored.Methods: 8 groups of 6 mice each were evaluated for anti-depressant effect in Tail Suspension...
Since Domino and colleagues reported the first clinical use of ketamine more than half a century ago...
Background: Depression is a common psychiatric disorder that has become the leading cause of disabil...
Depression affects more than 350 million people and is the leading cause of disability worldwide. Ma...
Background: The prevalence of depression is highest amongst the mood disorders. Nearly one third of ...
Ketamine is an anesthetic with antidepressant properties. The rapid and lasting effect of ketamine o...
An increasing amount of research suggests Ketamine in subanaesthetic doses to be an effective antide...
The N-methyl-D-aspartate (NMDA) receptor antagonist ketamine is one of the most attractive antidepre...
The National Institutes of Mental Health has portrayed major depressive disorder (MDD) to affect app...
Approximately 10% of children and adolescents are diagnosed with major depressive disorder (MDD). Cu...
Ketamine (KET), a NMDA receptor antagonist, has been studied for its rapid and efficacious antidepre...
The emergence of rapid-acting antidepressants such as ketamine has motivated studies aiming to revea...
Therapeutic medications for the treatment of depression have serious limitations, particularly delay...
Major depression is a stress-linked disease with significant morbidity and the anesthetic drug ketam...
-methyl-D-aspartate (NMDA) receptor antagonist, ketamine, induces rapid antidepressant effects in pa...
Major depression is a stress-linked disease with significant morbidity and the anesthetic drug ketam...
Since Domino and colleagues reported the first clinical use of ketamine more than half a century ago...
Background: Depression is a common psychiatric disorder that has become the leading cause of disabil...
Depression affects more than 350 million people and is the leading cause of disability worldwide. Ma...
Background: The prevalence of depression is highest amongst the mood disorders. Nearly one third of ...
Ketamine is an anesthetic with antidepressant properties. The rapid and lasting effect of ketamine o...
An increasing amount of research suggests Ketamine in subanaesthetic doses to be an effective antide...
The N-methyl-D-aspartate (NMDA) receptor antagonist ketamine is one of the most attractive antidepre...
The National Institutes of Mental Health has portrayed major depressive disorder (MDD) to affect app...
Approximately 10% of children and adolescents are diagnosed with major depressive disorder (MDD). Cu...
Ketamine (KET), a NMDA receptor antagonist, has been studied for its rapid and efficacious antidepre...
The emergence of rapid-acting antidepressants such as ketamine has motivated studies aiming to revea...
Therapeutic medications for the treatment of depression have serious limitations, particularly delay...
Major depression is a stress-linked disease with significant morbidity and the anesthetic drug ketam...
-methyl-D-aspartate (NMDA) receptor antagonist, ketamine, induces rapid antidepressant effects in pa...
Major depression is a stress-linked disease with significant morbidity and the anesthetic drug ketam...
Since Domino and colleagues reported the first clinical use of ketamine more than half a century ago...
Background: Depression is a common psychiatric disorder that has become the leading cause of disabil...
Depression affects more than 350 million people and is the leading cause of disability worldwide. Ma...